The ongoing mission of the Michigan Cancer Research Consortium (MCRC) CCOP has been to improve the oncologic health of the communities it serves by assuring access to and participation in state-of-the-art clinical trials and cancer prevention and control activities while contributing to knowledge development in the field of oncology care. Over the past 20 years, the MCRC represents a proven resource with significant potential to serve the objectives of the National Cancer Institute's NCORP program. First funded in 1994 as a single component CCOP, the MCRC is now comprised of thirteen health systems and 150+ oncology investigators from 50+ practices in three states. MCRC has registered over 7,700 patients to trials. Annual accrual approaches 400+ credits and the MCRC's organizational efficiencies are among the best models in the country. Additional value is added as the primary awardee and lead institution of the MCRC, Saint Joseph Mercy Health System, actively contributed to the National Community Cancer Centers Program (NCCCP) from 2010-2012. Participation provided MCRC with experience and growth in key areas of importance to the NCORP program by increasing access to care, participating in Cancer Care Delivery Research, and improving quality of care across the continuum and participation in biospecimen banking. MCRC has already sought resources and experiences to assure development of infrastructure to master Cancer Care Delivery Research. Our experience positions us for success given our proven track record in clinical trials and competency and strategic partnerships to be active members of the NCTN's Cancer Care Delivery Research program. This grant proposal encompasses and articulates a vision that the MCRC will be a productive member of the newly developed NCORP program.
The NCORP Community Sites will accrue patients/participants to NCI-approved cancer clinical trials and cancer care delivery research (CCDR). The MCRC, which is the largest community research consortium in the state of Michigan serving the adult populations, has successfully incorporated CCDR and has capacity to successfully assist the NCI in meeting the goals of the NCORP in a multi-state initiative.
|Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650|
|McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31|
|West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92|
|Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332|
|Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504|
|Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703|
|Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522|
|Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753|
|McWilliams, Robert R; Foster, Nathan R; Mahoney, Michelle R et al. (2017) North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 123:3494-3501|
|Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465|
Showing the most recent 10 out of 19 publications